Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BSD's MicroThermX microwave ablation system available in Europe

This article was originally published in Clinica

Executive Summary

BSD Medical has CE marked its MicroThermX microwave ablation system (MTX-180) for sale in Europe. The device is designed to treat cancer by using microwave energy to ablate soft tissue, delivered via a single-use disposable antenna. MTX-180 received 510(k) clearance from the US FDA in August (www.clinica.co.uk, 19 August 2010). Salt Lake City, Utah-based BSD estimates that the worldwide soft tissue ablation oncology market will reach $2bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel